QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
Free Trial
OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free NSPX Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
29.64 million shs
Average Volume
13.19 million shs
Market Capitalization
$1.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Inspyr Therapeutics

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

NSPX Stock News Headlines

April 4, 2024 | seekingalpha.com
EWTX Edgewise Therapeutics, Inc.
March 4, 2023 | benzinga.com
TG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, Predictions
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
October 12, 2021 | ca.finance.yahoo.com
Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock Split
See More Headlines
Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2017
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NSPX
CUSIP
N/A
CIK
1421204
Web
www.genspera.com
Phone
(818) 597-7552
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,300,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-1,354.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.09
Quick Ratio
0.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
543,152,000
Free Float
N/A
Market Cap
$1.47 million
Optionable
Not Optionable
Beta
-17.33
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Silvestre Raul
    President, Chief Executive Officer & Director
  • Michael Elliott
    Vice President-Clinical Operations

Key Competitors

View All Competitors

NSPX Stock Analysis - Frequently Asked Questions

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its quarterly earnings data on Monday, August, 14th. The company reported ($26.25) EPS for the quarter.

When did Inspyr Therapeutics' stock split?

Inspyr Therapeutics's stock reverse split on the morning of Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Cleveland BioLabs (CBLI), Cloudcall Group (CALL), Blink Charging (BLNK) and BIO-key International (BKYI).

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NSPX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research